Symbols / SCNX $0.31 +3.07% Scienture Holdings, Inc.
SCNX Chart
About
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company operates through Integra and Scienture segments. The Integra segment engages in the wholesale and sale of licensed pharmaceutical brand, generic, and non-drug products. The Scienture segment researches and develops branded pharmaceutical products. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is based in Tampa, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Pharmaceutical Retailers | Market Cap | 12.41M |
| Enterprise Value | 5.40M | Income | -41.51M | Sales | 431.61K |
| Book/sh | 1.73 | Cash/sh | 0.16 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | 0.32 | Forward P/E | -1.45 | PEG | — |
| P/S | 28.75 | P/B | 0.18 | P/C | — |
| EV/EBITDA | -0.34 | EV/Sales | 12.51 | Quick Ratio | 2.70 |
| Current Ratio | 2.89 | Debt/Eq | 0.03 | LT Debt/Eq | — |
| EPS (ttm) | -2.70 | EPS next Y | -0.21 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-30 08:00 | ROA | -10.74% |
| ROE | -55.65% | ROIC | — | Gross Margin | 76.80% |
| Oper. Margin | 18.70% | Profit Margin | 0.00% | Shs Outstand | 40.63M |
| Shs Float | 32.79M | Short Float | 8.86% | Short Ratio | 0.38 |
| Short Interest | — | 52W High | 2.60 | 52W Low | 0.24 |
| Beta | — | Avg Volume | 3.44M | Volume | 100.02K |
| Target Price | $1.50 | Recom | None | Prev Close | $0.30 |
| Price | $0.31 | Change | 3.07% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-24 | init | Maxim Group | — → Buy | $2 |
- Scienture lines up 5,000 sites for overdose spray launch in Q2 - stocktitan.net Mon, 06 Apr 2026 12
- Why Is Scienture Holdings Stock (SCNX) Up Today? - TipRanks Wed, 11 Mar 2026 07
- Market Movers | Winners: ELAB, BFRG, ASTC | Losers: SCNX, ORGN, HWH - Trefis ue, 31 Mar 2026 03
- If You Invested $1,000 in Scienture Holdings, Inc (SCNX) - stocktitan.net Sun, 22 Mar 2026 02
- Scienture Holdings: Q4 Earnings Snapshot - KTVB Mon, 30 Mar 2026 12
- Why Did Scienture Stock (SCNX) Soar 45% Today? - TipRanks hu, 23 Oct 2025 07
- High-dose overdose spray REZENOPY set to reach 5,000 US care sites - stocktitan.net Wed, 11 Mar 2026 07
- Scienture’s blood pressure drug drove 216% growth; overdose spray up next - stocktitan.net Mon, 30 Mar 2026 12
- Scienture (SCNX) Co-CEO adds stock grants and converts preferred into common - stocktitan.net hu, 12 Mar 2026 07
- Latest SCNX News - SCIENTURE Reports Year End 2025 Financial R... - stocktitan.net Wed, 14 Jan 2026 08
- Scienture Holdings (SCNX) Co-CEO granted 500,000 restricted shares - stocktitan.net hu, 12 Mar 2026 07
- Nearly $385M at stake as Scienture grows ARBLI and readies overdose REZENOPY - stocktitan.net ue, 03 Feb 2026 08
- Scienture (NASDAQ: SCNX) taps BlinkRx to launch Arbli, first ready-to-use losartan oral suspension in Q1 2026 - stocktitan.net Wed, 10 Dec 2025 08
- New patent backs 10 mg naloxone spray for life-saving overdose treatment - stocktitan.net Wed, 14 Jan 2026 08
- Scienture (NASDAQ: SCNX) launches Arbli, FDA-approved liquid losartan; revenue hits $590K - stocktitan.net hu, 13 Nov 2025 08
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.43
+215.87%
|
0.14
-89.98%
|
1.36
-86.69%
|
10.25
|
| Operating Revenue |
|
0.43
+215.87%
|
0.14
-89.98%
|
1.36
-86.69%
|
10.25
|
| Cost Of Revenue |
|
0.10
-23.36%
|
0.13
-90.06%
|
1.31
-72.21%
|
4.73
|
| Reconciled Cost Of Revenue |
|
0.10
-23.36%
|
0.13
-90.06%
|
1.31
-72.21%
|
4.73
|
| Gross Profit |
|
0.33
+5420.10%
|
0.01
-87.75%
|
0.05
-99.11%
|
5.52
|
| Operating Expense |
|
16.58
+12.71%
|
14.71
+230.83%
|
4.45
-41.20%
|
7.56
|
| Research And Development |
|
1.96
-12.54%
|
2.24
|
0.00
-100.00%
|
0.99
|
| Selling General And Administration |
|
14.52
+20.48%
|
12.05
+177.41%
|
4.35
-33.83%
|
6.57
|
| General And Administrative Expense |
|
14.52
+20.48%
|
12.05
+177.41%
|
4.35
-33.83%
|
6.57
|
| Salaries And Wages |
|
2.12
+0.36%
|
2.11
+236.94%
|
0.63
-82.50%
|
3.58
|
| Other Gand A |
|
12.40
+24.75%
|
9.94
+167.38%
|
3.72
+24.55%
|
2.99
|
| Other Operating Expenses |
|
0.10
-76.64%
|
0.42
+315.15%
|
0.10
-89.90%
|
0.99
|
| Total Expenses |
|
16.68
+12.39%
|
14.84
+157.59%
|
5.76
-53.13%
|
12.29
|
| Operating Income |
|
-16.24
-10.50%
|
-14.70
-234.38%
|
-4.40
-115.44%
|
-2.04
|
| Total Operating Income As Reported |
|
-42.59
-189.71%
|
-14.70
-234.38%
|
-4.40
-50.77%
|
-2.92
|
| EBITDA |
|
-38.93
-123.88%
|
-17.39
-176.48%
|
-6.29
-235.90%
|
-1.87
|
| Normalized EBITDA |
|
-15.50
-6.83%
|
-14.51
-334.19%
|
-3.34
-83.14%
|
-1.83
|
| Reconciled Depreciation |
|
0.49
+821.61%
|
0.05
-94.92%
|
1.05
+439.19%
|
0.19
|
| EBIT |
|
-39.42
-126.01%
|
-17.44
-137.66%
|
-7.34
-255.05%
|
-2.07
|
| Total Unusual Items |
|
-23.43
-714.17%
|
-2.88
+2.37%
|
-2.95
-6104.24%
|
-0.05
|
| Total Unusual Items Excluding Goodwill |
|
-23.43
-714.17%
|
-2.88
+2.37%
|
-2.95
-6104.24%
|
-0.05
|
| Special Income Charges |
|
-26.63
-826.42%
|
-2.87
-2.72%
|
-2.80
-220.60%
|
-0.87
|
| Impairment Of Capital Assets |
|
26.35
|
—
|
5.13
|
0.00
|
| Write Off |
|
0.00
-100.00%
|
2.50
|
0.00
-100.00%
|
0.88
|
| Net Income |
|
-41.51
-557.90%
|
9.07
+150.81%
|
-17.84
-413.91%
|
-3.47
|
| Pretax Income |
|
-43.51
-131.68%
|
-18.78
-121.37%
|
-8.48
-252.95%
|
-2.40
|
| Net Non Operating Interest Income Expense |
|
-3.78
-214.96%
|
-1.20
-5.38%
|
-1.14
-261.35%
|
-0.32
|
| Interest Expense Non Operating |
|
4.08
+205.71%
|
1.34
+16.83%
|
1.14
+240.04%
|
0.34
|
| Net Interest Income |
|
-3.78
-214.96%
|
-1.20
-5.38%
|
-1.14
-261.35%
|
-0.32
|
| Interest Expense |
|
4.08
+205.71%
|
1.34
+16.83%
|
1.14
+240.04%
|
0.34
|
| Interest Income Non Operating |
|
0.30
+123.67%
|
0.14
+3123.84%
|
0.00
-80.00%
|
0.02
|
| Interest Income |
|
0.30
+123.67%
|
0.14
+3123.84%
|
0.00
-80.00%
|
0.02
|
| Other Income Expense |
|
-23.48
-716.03%
|
-2.88
+2.37%
|
-2.95
-6104.24%
|
-0.05
|
| Other Non Operating Income Expenses |
|
-0.05
|
—
|
0.01
|
—
|
| Gain On Sale Of Security |
|
3.21
+123449.52%
|
-0.00
+98.25%
|
-0.15
-117.98%
|
0.83
|
| Gain On Sale Of Business |
|
-0.29
|
0.00
|
—
|
—
|
| Tax Provision |
|
-1.99
-273.30%
|
-0.53
|
0.00
|
—
|
| Tax Rate For Calcs |
|
0.00
+61.13%
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
-1.07
-1211.84%
|
-0.08
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-41.51
-557.90%
|
9.07
+150.81%
|
-17.84
-356.37%
|
-3.91
|
| Net Income From Continuing Operation Net Minority Interest |
|
-41.51
-127.53%
|
-18.24
-115.07%
|
-8.48
-331.55%
|
-1.97
|
| Net Income From Continuing And Discontinued Operation |
|
-41.51
-557.90%
|
9.07
+150.81%
|
-17.84
-413.91%
|
-3.47
|
| Net Income Continuous Operations |
|
-41.51
-127.53%
|
-18.24
-115.07%
|
-8.48
-252.95%
|
-2.40
|
| Net Income Discontinuous Operations |
|
0.00
-100.00%
|
27.31
+391.75%
|
-9.36
-521.39%
|
-1.51
|
| Minority Interests |
|
—
|
—
|
0.00
-100.00%
|
0.44
|
| Normalized Income |
|
-19.16
-24.01%
|
-15.45
-179.09%
|
-5.54
-188.58%
|
-1.92
|
| Net Income Common Stockholders |
|
-41.51
-557.90%
|
9.07
+150.81%
|
-17.84
-413.91%
|
-3.47
|
| Diluted EPS |
|
-2.70
-208.87%
|
2.48
+110.62%
|
-23.35
-279.67%
|
-6.15
|
| Basic EPS |
|
-2.70
-200.37%
|
2.69
+111.52%
|
-23.35
-279.67%
|
-6.15
|
| Basic Average Shares |
|
15.35
+354.69%
|
3.38
+341.76%
|
0.76
+35.26%
|
0.56
|
| Diluted Average Shares |
|
15.35
+320.06%
|
3.65
+53.42%
|
2.38
+321.60%
|
0.56
|
| Diluted NI Availto Com Stockholders |
|
-41.51
-557.90%
|
9.07
+150.81%
|
-17.84
-413.91%
|
-3.47
|
| Gain On Sale Of PPE |
|
0.00
+100.00%
|
-0.37
+86.60%
|
-2.80
-127325.82%
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
84.18
-19.72%
|
104.85
+736.63%
|
12.53
+237.81%
|
3.71
|
| Current Assets |
|
7.92
+25.55%
|
6.31
+129.03%
|
2.75
+31.53%
|
2.09
|
| Cash Cash Equivalents And Short Term Investments |
|
6.66
+2062.32%
|
0.31
+98019.75%
|
0.00
-99.97%
|
1.09
|
| Cash And Cash Equivalents |
|
6.66
+2062.32%
|
0.31
+98019.75%
|
0.00
-99.97%
|
1.09
|
| Cash Financial |
|
6.66
+2062.32%
|
0.31
+98019.75%
|
0.00
-99.97%
|
1.09
|
| Receivables |
|
0.73
-86.58%
|
5.45
+115.86%
|
2.52
+300.80%
|
0.63
|
| Accounts Receivable |
|
0.73
+6484.98%
|
0.01
|
0.00
-100.00%
|
0.63
|
| Gross Accounts Receivable |
|
—
|
—
|
0.85
+17.17%
|
0.73
|
| Allowance For Doubtful Accounts Receivable |
|
—
|
—
|
-0.03
+67.55%
|
-0.10
|
| Other Receivables |
|
—
|
4.14
+237.94%
|
1.22
|
—
|
| Inventory |
|
0.21
|
0.00
-100.00%
|
0.00
-98.52%
|
0.07
|
| Raw Materials |
|
—
|
—
|
0.00
-100.00%
|
0.07
|
| Finished Goods |
|
0.21
|
0.00
-100.00%
|
0.00
|
0.00
|
| Prepaid Assets |
|
0.26
+5651.71%
|
0.00
-91.01%
|
0.05
-51.44%
|
0.10
|
| Current Deferred Assets |
|
0.05
-91.14%
|
0.53
|
0.00
|
—
|
| Assets Held For Sale Current |
|
0.00
-100.00%
|
0.01
-95.38%
|
0.18
-11.08%
|
0.20
|
| Total Non Current Assets |
|
76.26
-22.61%
|
98.55
+907.67%
|
9.78
+504.85%
|
1.62
|
| Net PPE |
|
0.04
-82.25%
|
0.22
+10.17%
|
0.20
-82.21%
|
1.12
|
| Gross PPE |
|
0.04
-82.25%
|
0.22
+10.17%
|
0.20
-82.21%
|
1.12
|
| Other Properties |
|
0.04
-82.25%
|
0.22
+10.17%
|
0.20
-82.21%
|
1.12
|
| Goodwill And Other Intangible Assets |
|
70.97
-27.41%
|
97.77
|
0.00
|
0.00
|
| Goodwill |
|
0.00
-100.00%
|
21.37
|
0.00
|
—
|
| Other Intangible Assets |
|
70.97
-7.10%
|
76.40
+752.42%
|
8.96
|
—
|
| Non Current Accounts Receivable |
|
0.25
|
—
|
—
|
—
|
| Non Current Deferred Assets |
|
0.00
-100.00%
|
0.53
|
—
|
—
|
| Non Current Deferred Taxes Assets |
|
0.00
-100.00%
|
0.53
|
—
|
—
|
| Non Current Prepaid Assets |
|
0.00
-100.00%
|
0.02
+109.28%
|
0.01
-78.52%
|
0.05
|
| Other Non Current Assets |
|
—
|
—
|
9.57
+2022.81%
|
0.45
|
| Total Liabilities Net Minority Interest |
|
14.06
-45.47%
|
25.78
+115.02%
|
11.99
+256.10%
|
3.37
|
| Current Liabilities |
|
2.74
-65.41%
|
7.91
-31.58%
|
11.56
+438.31%
|
2.15
|
| Payables And Accrued Expenses |
|
2.10
-50.14%
|
4.21
+159.51%
|
1.62
+88.40%
|
0.86
|
| Payables |
|
1.44
-50.21%
|
2.90
+98.13%
|
1.46
+147.81%
|
0.59
|
| Accounts Payable |
|
1.44
-50.21%
|
2.90
+98.13%
|
1.46
+177.09%
|
0.53
|
| Other Payable |
|
—
|
—
|
0.42
+573.68%
|
0.06
|
| Current Accrued Expenses |
|
0.66
-49.99%
|
1.31
+719.99%
|
0.16
-40.93%
|
0.27
|
| Current Debt And Capital Lease Obligation |
|
0.02
-99.13%
|
2.76
+8379.08%
|
0.03
-91.03%
|
0.36
|
| Current Debt |
|
—
|
2.70
-58.65%
|
6.53
+3817.99%
|
0.17
|
| Other Current Borrowings |
|
—
|
2.70
-58.65%
|
6.53
+3817.99%
|
0.17
|
| Current Capital Lease Obligation |
|
0.02
-61.89%
|
0.06
+94.31%
|
0.03
-83.44%
|
0.20
|
| Current Deferred Liabilities |
|
—
|
—
|
0.00
-100.00%
|
0.01
|
| Current Deferred Revenue |
|
—
|
—
|
0.00
-100.00%
|
0.01
|
| Other Current Liabilities |
|
0.61
-34.36%
|
0.93
-90.60%
|
9.90
+980.23%
|
0.92
|
| Total Non Current Liabilities Net Minority Interest |
|
11.32
-36.66%
|
17.87
+4016.67%
|
0.43
-64.42%
|
1.22
|
| Liabilities Heldfor Sale Non Current |
|
—
|
0.00
-100.00%
|
0.26
|
—
|
| Long Term Debt And Capital Lease Obligation |
|
0.00
-100.00%
|
0.77
+334.54%
|
0.18
-85.50%
|
1.22
|
| Long Term Debt |
|
—
|
0.61
+2349.10%
|
0.03
-92.50%
|
0.33
|
| Long Term Capital Lease Obligation |
|
0.00
-100.00%
|
0.16
-11.55%
|
0.18
-80.06%
|
0.89
|
| Non Current Deferred Liabilities |
|
11.04
-18.39%
|
13.52
|
—
|
—
|
| Non Current Deferred Taxes Liabilities |
|
11.04
-18.39%
|
13.52
|
—
|
—
|
| Other Non Current Liabilities |
|
0.28
-77.82%
|
1.28
|
—
|
—
|
| Stockholders Equity |
|
70.12
-11.32%
|
79.07
+14479.46%
|
0.54
-28.93%
|
0.76
|
| Common Stock Equity |
|
70.12
-11.32%
|
79.07
+14479.46%
|
0.54
-28.93%
|
0.76
|
| Capital Stock |
|
0.00
+366.67%
|
0.00
+866.67%
|
0.00
+50.00%
|
0.00
|
| Common Stock |
|
0.00
+366.67%
|
0.00
+866.67%
|
0.00
+50.00%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
40.63
+364.32%
|
8.75
+866.91%
|
0.91
+44.51%
|
0.63
|
| Ordinary Shares Number |
|
40.63
+364.32%
|
8.75
+866.91%
|
0.91
+44.51%
|
0.63
|
| Additional Paid In Capital |
|
150.67
+27.57%
|
118.11
+249.56%
|
33.79
+64.96%
|
20.48
|
| Retained Earnings |
|
-80.55
-106.34%
|
-39.04
-17.42%
|
-33.25
-68.59%
|
-19.72
|
| Minority Interest |
|
—
|
—
|
0.00
+100.00%
|
-0.42
|
| Total Equity Gross Minority Interest |
|
70.12
-11.32%
|
79.07
+14479.46%
|
0.54
+58.18%
|
0.34
|
| Total Capitalization |
|
70.12
-12.00%
|
79.68
+14592.35%
|
0.54
-50.54%
|
1.10
|
| Working Capital |
|
5.18
+423.53%
|
-1.60
+81.81%
|
-8.80
-16303.24%
|
-0.05
|
| Invested Capital |
|
70.12
-14.89%
|
82.38
+15090.26%
|
0.54
-57.06%
|
1.26
|
| Total Debt |
|
0.02
-99.32%
|
3.53
+1586.13%
|
0.21
-86.77%
|
1.58
|
| Net Debt |
|
—
|
3.00
-53.08%
|
6.40
|
—
|
| Capital Lease Obligations |
|
0.02
-89.02%
|
0.22
+4.92%
|
0.21
-80.67%
|
1.08
|
| Net Tangible Assets |
|
-0.85
+95.44%
|
-18.70
-3548.09%
|
0.54
-28.93%
|
0.76
|
| Tangible Book Value |
|
-0.85
+95.44%
|
-18.70
-3548.09%
|
0.54
-28.93%
|
0.76
|
| Current Notes Payable |
|
—
|
—
|
—
|
0.17
|
| Derivative Product Liabilities |
|
0.00
-100.00%
|
2.30
|
0.00
|
—
|
| Non Current Note Receivables |
|
5.00
|
0.00
|
—
|
—
|
| Notes Receivable |
|
0.00
-100.00%
|
1.30
+0.00%
|
1.30
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-13.38
+6.21%
|
-14.27
-541.08%
|
-2.23
-42.21%
|
-1.56
|
| Cash Flow From Continuing Operating Activities |
|
-13.38
-0.72%
|
-13.29
-464.48%
|
3.65
+1931.60%
|
-0.20
|
| Cash From Discontinued Operating Activities |
|
0.00
+100.29%
|
-0.98
+83.32%
|
-5.87
-329.87%
|
-1.37
|
| Net Income From Continuing Operations |
|
-43.51
-131.68%
|
-18.78
-121.37%
|
-8.48
-252.95%
|
-2.40
|
| Depreciation Amortization Depletion |
|
0.49
+821.61%
|
0.05
-94.92%
|
1.05
+439.19%
|
0.19
|
| Depreciation |
|
0.04
-28.91%
|
0.05
-77.30%
|
0.24
+20.72%
|
0.19
|
| Amortization Cash Flow |
|
0.45
|
0.00
-100.00%
|
0.81
|
0.00
|
| Depreciation And Amortization |
|
0.49
+821.61%
|
0.05
-94.92%
|
1.05
+439.19%
|
0.19
|
| Amortization Of Intangibles |
|
0.45
|
0.00
-100.00%
|
0.81
|
0.00
|
| Other Non Cash Items |
|
7.27
+32.01%
|
5.51
+2037.84%
|
0.26
+1.44%
|
0.25
|
| Stock Based Compensation |
|
2.07
+7986.66%
|
0.03
-90.07%
|
0.26
+1.44%
|
0.25
|
| Asset Impairment Charge |
|
26.35
+953.84%
|
2.50
-51.26%
|
5.13
+260.93%
|
1.42
|
| Operating Gains Losses |
|
-2.99
-115196.88%
|
0.00
-98.54%
|
0.18
+131.49%
|
0.08
|
| Gain Loss On Investment Securities |
|
-3.21
-123449.52%
|
0.00
-98.54%
|
0.18
+125.05%
|
0.08
|
| Change In Working Capital |
|
-3.07
-17.92%
|
-2.60
-147.15%
|
5.51
+2040.39%
|
0.26
|
| Change In Receivables |
|
-0.80
+72.63%
|
-2.93
-433.10%
|
-0.55
-8.59%
|
-0.51
|
| Changes In Account Receivables |
|
-0.72
-6384.98%
|
-0.01
+96.22%
|
-0.29
-179.42%
|
0.37
|
| Change In Inventory |
|
-0.21
-22146.28%
|
0.00
-99.98%
|
4.23
+8281.66%
|
-0.05
|
| Change In Prepaid Assets |
|
-0.19
-656.97%
|
0.03
-9.67%
|
0.04
-88.55%
|
0.34
|
| Change In Payables And Accrued Expense |
|
-1.82
-549.50%
|
0.40
-79.97%
|
2.02
+17099.55%
|
-0.01
|
| Change In Accrued Expense |
|
-0.25
-457.14%
|
-0.04
-176.02%
|
0.06
+127.72%
|
-0.21
|
| Change In Payable |
|
-1.57
-449.38%
|
0.45
-77.09%
|
1.96
+879.63%
|
0.20
|
| Change In Account Payable |
|
-1.57
-449.38%
|
0.45
-72.10%
|
1.61
+704.48%
|
0.20
|
| Change In Other Working Capital |
|
—
|
—
|
—
|
—
|
| Change In Other Current Assets |
|
—
|
—
|
0.31
|
0.00
|
| Change In Other Current Liabilities |
|
-0.04
+62.78%
|
-0.11
+49.50%
|
-0.23
-145.92%
|
0.49
|
| Investing Cash Flow |
|
0.00
-100.00%
|
27.55
+10093.14%
|
-0.28
+35.56%
|
-0.43
|
| Cash Flow From Continuing Investing Activities |
|
0.00
+100.00%
|
-2.38
-590.67%
|
-0.34
-46088.52%
|
0.00
|
| Cash From Discontinued Investing Activities |
|
0.00
-100.00%
|
29.93
+43445.42%
|
0.07
+116.04%
|
-0.43
|
| Net PPE Purchase And Sale |
|
0.00
+100.00%
|
-0.01
|
0.00
-100.00%
|
0.00
|
| Purchase Of PPE |
|
0.00
+100.00%
|
-0.01
|
—
|
0.00
|
| Sale Of PPE |
|
—
|
—
|
0.00
-100.00%
|
0.00
|
| Capital Expenditure |
|
—
|
-0.01
|
—
|
-0.45
|
| Capital Expenditure Reported |
|
—
|
—
|
0.00
|
0.00
|
| Net Investment Purchase And Sale |
|
0.00
+100.00%
|
-2.50
|
0.00
|
—
|
| Purchase Of Investment |
|
0.00
+100.00%
|
-2.50
|
0.00
|
—
|
| Net Business Purchase And Sale |
|
0.00
-100.00%
|
0.13
+138.60%
|
-0.34
|
0.00
|
| Purchase Of Business |
|
—
|
0.00
+100.00%
|
-0.34
|
0.00
|
| Gain Loss On Sale Of Business |
|
0.21
|
0.00
|
—
|
—
|
| Net Other Investing Changes |
|
—
|
-0.01
|
—
|
—
|
| Financing Cash Flow |
|
19.73
+252.03%
|
-12.98
-1022.95%
|
1.41
+4098.56%
|
-0.04
|
| Cash Flow From Continuing Financing Activities |
|
19.73
+252.09%
|
-12.97
-780.61%
|
1.91
+694.87%
|
0.24
|
| Net Issuance Payments Of Debt |
|
-6.16
-298.44%
|
3.10
+1141.60%
|
0.25
|
0.00
|
| Issuance Of Debt |
|
3.62
+16.49%
|
3.10
+676.00%
|
0.40
|
0.00
|
| Repayment Of Debt |
|
-9.78
|
0.00
+100.00%
|
-0.15
|
0.00
|
| Long Term Debt Issuance |
|
3.62
+16.49%
|
3.10
+676.00%
|
0.40
|
0.00
|
| Long Term Debt Payments |
|
-9.78
|
0.00
+100.00%
|
-0.15
|
0.00
|
| Net Long Term Debt Issuance |
|
-6.16
-298.44%
|
3.10
+1141.60%
|
0.25
|
0.00
|
| Short Term Debt Payments |
|
—
|
—
|
—
|
—
|
| Net Short Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Common Stock Issuance |
|
26.29
|
0.00
|
0.00
-100.00%
|
0.13
|
| Common Stock Dividend Paid |
|
0.00
+100.00%
|
-14.86
|
0.00
|
—
|
| Cash Dividends Paid |
|
0.00
+100.00%
|
-14.86
|
0.00
|
—
|
| Proceeds From Stock Option Exercised |
|
0.00
-100.00%
|
0.03
+1528.05%
|
0.00
+85.37%
|
0.00
|
| Net Other Financing Charges |
|
-0.40
+67.91%
|
-1.25
-175.32%
|
1.65
+1431.63%
|
0.11
|
| Changes In Cash |
|
6.35
+1964.42%
|
0.31
+128.12%
|
-1.09
+46.02%
|
-2.03
|
| Beginning Cash Position |
|
0.31
+98019.75%
|
0.00
-99.97%
|
1.09
-64.94%
|
3.12
|
| End Cash Position |
|
6.66
+2062.32%
|
0.31
+98019.75%
|
0.00
-99.97%
|
1.09
|
| Free Cash Flow |
|
-13.38
+6.29%
|
-14.28
-541.62%
|
-2.23
-42.21%
|
-1.56
|
| Interest Paid Supplemental Data |
|
0.00
|
0.00
-100.00%
|
0.73
+118.23%
|
0.34
|
| Income Tax Paid Supplemental Data |
|
—
|
0.00
|
0.00
|
0.00
|
| Common Stock Issuance |
|
26.29
|
0.00
|
0.00
-100.00%
|
0.13
|
| Issuance Of Capital Stock |
|
26.29
|
0.00
|
0.00
-100.00%
|
0.13
|
| Sale Of Business |
|
0.00
-100.00%
|
0.13
|
0.00
|
—
|
| Cash From Discontinued Financing Activities |
|
0.00
+100.00%
|
-0.01
+99.00%
|
-0.50
-81.82%
|
-0.28
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-30 View
- 42026-03-12 View
- 42026-03-12 View
- 8-K2025-11-18 View
- 8-K2025-11-14 View
- 8-K2025-11-13 View
- 10-Q2025-11-12 View
- 8-K2025-10-30 View
- 8-K2025-10-24 View
- 8-K2025-10-17 View
- 8-K2025-10-16 View
- 8-K2025-10-06 View
- 8-K2025-10-03 View
- 8-K2025-09-23 View
- 8-K2025-08-15 View
- 10-Q2025-08-12 View
- 8-K2025-07-24 View
- 8-K2025-07-03 View
- 8-K2025-05-22 View
- 10-Q2025-05-12 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|